{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:25:55Z","timestamp":1784589955556,"version":"3.55.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s11864-020-00809-w","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T21:03:26Z","timestamp":1610053406000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Mycosis Fungoides and S\u00e9zary Syndrome: Updates and Review of Current Therapy"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5687-3076","authenticated-orcid":false,"given":"Hiroaki","family":"Kamijo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomitsu","family":"Miyagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"issue":"10","key":"809_CR1","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","volume":"105","author":"R Willemze","year":"2005","unstructured":"Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768\u201385. https:\/\/doi.org\/10.1182\/blood-2004-09-3502.","journal-title":"Blood"},{"issue":"3","key":"809_CR2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjd.17240","volume":"180","author":"D Gilson","year":"2019","unstructured":"Gilson D, Whittaker SJ, Child FJ, Scarisbrick JJ, Illidge TM, Parry EJ, et al. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol. 2019;180(3):496\u2013526. https:\/\/doi.org\/10.1111\/bjd.17240.","journal-title":"Br J Dermatol"},{"issue":"31","key":"809_CR3","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","volume":"28","author":"NS Agar","year":"2010","unstructured":"Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730\u20139. https:\/\/doi.org\/10.1200\/JCO.2009.27.7665.","journal-title":"J Clin Oncol"},{"issue":"26","key":"809_CR4","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","volume":"321","author":"FJ Kaye","year":"1989","unstructured":"Kaye FJ, Bunn PA, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989;321(26):1784\u201390. https:\/\/doi.org\/10.1056\/NEJM198912283212603.","journal-title":"N Engl J Med"},{"issue":"1","key":"809_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","volume":"125","author":"CFM Hughes","year":"2015","unstructured":"Hughes CFM, Khot A, McCormack C, Lade S, Westerman DA, Twigger R, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: a comparative study of systemic therapy. Blood. 2015;125(1):71\u201381. https:\/\/doi.org\/10.1182\/blood-2014-07-588236.","journal-title":"Blood"},{"issue":"2","key":"809_CR6","doi-asserted-by":"publisher","first-page":"205.e1","DOI":"10.1016\/j.jaad.2013.07.049","volume":"70","author":"SI Jawed","year":"2014","unstructured":"Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome). J Am Acad Dermatol. 2014;70(2):205.e1\u2013205.e16. https:\/\/doi.org\/10.1016\/j.jaad.2013.07.049.","journal-title":"J Am Acad Dermatol"},{"issue":"D","key":"809_CR7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/archderm.134.8.949","volume":"134","author":"HS Zackheim","year":"1998","unstructured":"Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides: experience in 79 patients. Arch Dermatol. 1998;134(D):949\u201354. https:\/\/doi.org\/10.1001\/archderm.134.8.949.","journal-title":"Arch Dermatol"},{"issue":"2","key":"809_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/archderm.139.2.165","volume":"139","author":"YH Kim","year":"2003","unstructured":"Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003;139(2):165\u201373. https:\/\/doi.org\/10.1001\/archderm.139.2.165.","journal-title":"Arch Dermatol"},{"issue":"3","key":"809_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/bjd.12620","volume":"170","author":"LM Lindahl","year":"2014","unstructured":"Lindahl LM, Fenger-Gr\u00f8n M, Iversen L. Secondary cancers, comorbidities and mortality associated with nitrogen mustard therapy in patients with mycosis fungoides: a 30-year population-based cohort study. Br J Dermatol. 2014;170(3):699\u2013704. https:\/\/doi.org\/10.1111\/bjd.12620.","journal-title":"Br J Dermatol"},{"issue":"1","key":"809_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","volume":"149","author":"SR Lessin","year":"2013","unstructured":"Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149(1):25\u201332. https:\/\/doi.org\/10.1001\/2013.jamadermatol.541.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"809_CR11","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/0190-9622(90)70112-U","volume":"22","author":"HS Zackheim","year":"1990","unstructured":"Zackheim HS, Epstein EH, Crain WR. Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol. 1990;22(5):802\u201310. https:\/\/doi.org\/10.1016\/0190-9622(90)70112-U.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"809_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1001\/archderm.138.3.325","volume":"138","author":"D Breneman","year":"2002","unstructured":"Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002;138(3):325\u201332. https:\/\/doi.org\/10.1001\/archderm.138.3.325.","journal-title":"Arch Dermatol"},{"issue":"5","key":"809_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","volume":"49","author":"P Heald","year":"2003","unstructured":"Heald P, Mehlmauer M, Martin AG, Crowley CA, Yocum RC, Reich SD. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. 2003;49(5):801\u201315. https:\/\/doi.org\/10.1016\/S0190-9622(03)01475-0.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"809_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1001\/jamadermatol.2018.5204","volume":"155","author":"K Phan","year":"2019","unstructured":"\u2022\u2022 Phan K, Ramachandran V, Fassihi H, Sebaratnam DF. Comparison of narrowband UV-B with psoralen-UV-A phototherapy for patients with early-stage mycosis fungoides: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(3):335\u201341. https:\/\/doi.org\/10.1001\/jamadermatol.2018.5204 A meta-analysis of seven studies including 778 patients with stage IA\u2013IIA MF revealed that CR rate was significantly higher in patients treated with PUVA. CR was found to be 73.8% (389\/527) for patients who received PUVA compared with 62.2% (156\/251) for those who received NBUVB.","journal-title":"JAMA Dermatol"},{"issue":"8225","key":"809_CR15","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S0140-6736(81)92137-1","volume":"317","author":"T Henseler","year":"1981","unstructured":"Henseler T, H\u00f6nigsmann H, Wolff K, Christophers E. Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA study: a cooperative study among 18 European centres. Lancet. 1981;317(8225):853\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(81)92137-1.","journal-title":"Lancet"},{"issue":"4","key":"809_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jaad.2011.04.004","volume":"66","author":"RS Stern","year":"2012","unstructured":"Stern RS. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol. 2012;66(4):553\u201362. https:\/\/doi.org\/10.1016\/j.jaad.2011.04.004.","journal-title":"J Am Acad Dermatol"},{"key":"809_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1468-3083.2012.04520.x","volume":"26","author":"E Archier","year":"2012","unstructured":"Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Ma\u00eetre M, et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26:22\u201331. https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04520.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"809_CR18","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1001\/jamadermatol.2018.5905","volume":"155","author":"P Vieyra-Garcia","year":"2019","unstructured":"Vieyra-Garcia P, Fink-Puches R, Porkert S, Lang R, P\u00f6chlauer S, Ratzinger G, et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: a randomized clinical trial. JAMA Dermatol. 2019;155(5):538\u201347. https:\/\/doi.org\/10.1001\/jamadermatol.2018.5905.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"809_CR19","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/j.1365-4632.2004.02322.x","volume":"44","author":"JE Murase","year":"2005","unstructured":"Murase JE, Lee EE, Koo J. Effect of ethnicity on the risk of developing nonmelanoma skin cancer following long-term PUVA therapy. Int J Dermatol. 2005;44(12):1016\u201321. https:\/\/doi.org\/10.1111\/j.1365-4632.2004.02322.x.","journal-title":"Int J Dermatol"},{"issue":"4","key":"809_CR20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.1365-2133.2007.08415.x","volume":"158","author":"JJ Scarisbrick","year":"2008","unstructured":"Scarisbrick JJ, Taylor P, Holtick U, Makar Y, Douglas K, Berlin G, et al. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol. 2008;158(4):659\u201378. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08415.x.","journal-title":"Br J Dermatol"},{"issue":"16","key":"809_CR21","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1182\/blood.2019000765","volume":"134","author":"C Gao","year":"2019","unstructured":"Gao C, McCormack C, Van Der Weyden C, Goh MS, Campbell BA, Twigger R, et al. Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with S\u00e9zary syndrome. Blood. 2019;134(16):1346\u201350. https:\/\/doi.org\/10.1182\/blood.2019000765.","journal-title":"Blood"},{"issue":"6","key":"809_CR22","first-page":"565","volume":"62","author":"RL Edelson","year":"1989","unstructured":"Edelson RL. Photopheresis: a new therapeutic concept. Yale J Biol Med. 1989;62(6):565\u201377.","journal-title":"Yale J Biol Med"},{"issue":"6","key":"809_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/NEJM198702053160603","volume":"316","author":"R Edelson","year":"1987","unstructured":"Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med. 1987;316(6):297\u2013303. https:\/\/doi.org\/10.1056\/NEJM198702053160603.","journal-title":"N Engl J Med"},{"issue":"8","key":"809_CR24","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1001\/archderm.138.8.1054","volume":"138","author":"KR Suchin","year":"2002","unstructured":"Suchin KR, Cucchiara AJ, Gottleib SL, Wolfe JT, DeNardo BJ, Macey WH, et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch Dermatol. 2002;138(8):1054\u201360. https:\/\/doi.org\/10.1001\/archderm.138.8.1054.","journal-title":"Arch Dermatol"},{"issue":"1 1","key":"809_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1067\/mjd.2000.105510","volume":"43","author":"LD Wilson","year":"2000","unstructured":"Wilson LD, Jones GW, Kim D, Rosenthal D, Christensen IR, Edelson RL, et al. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol. 2000;43(1 1):54\u201360. https:\/\/doi.org\/10.1067\/mjd.2000.105510.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"809_CR26","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.ijrobp.2012.05.034","volume":"85","author":"TO Thomas","year":"2013","unstructured":"Thomas TO, Agrawal P, Guitart J, Rosen ST, Rademaker AW, Querfeld C, et al. Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2013;85(3):747\u201353. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.05.034.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"809_CR27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ijrobp.2008.06.1918","volume":"74","author":"KJ Neelis","year":"2009","unstructured":"Neelis KJ, Schimmel EC, Vermeer MH, Senff NJ, Willemze R, Noordijk EM. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys. 2009;74(1):154\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.06.1918.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"809_CR28","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1067\/mjd.2002.123482","volume":"47","author":"GW Jones","year":"2002","unstructured":"Jones GW, Kacinski BM, Wilson LD, Willemze R, Spittle M, Hohenberg G, et al. Total skin electron radiation in the management of mycosis fungoides: consensus of the european organization for research and treatment of cancer (EORTC) cutaneous lymphoma project group. J Am Acad Dermatol. 2002;47(3):364\u201370. https:\/\/doi.org\/10.1067\/mjd.2002.123482.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"809_CR29","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.clml.2016.08.019","volume":"16","author":"M Chowdhary","year":"2016","unstructured":"Chowdhary M, Chhabra AM, Kharod S, Marwaha G. Total skin electron beam therapy in the treatment of mycosis fungoides: a review of conventional and low-dose regimens. Clin Lymphoma Myeloma Leuk. 2016;16(12):662\u201371. https:\/\/doi.org\/10.1016\/j.clml.2016.08.019.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"809_CR30","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archdermatol.2011.98","volume":"147","author":"D Navi","year":"2011","unstructured":"Navi D, Riaz N, Levin YS, Sullivan NC, Kim YH, Hoppe RT. The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. Arch Dermatol. 2011;147(5):561\u20137. https:\/\/doi.org\/10.1001\/archdermatol.2011.98.","journal-title":"Arch Dermatol"},{"key":"809_CR31","doi-asserted-by":"publisher","unstructured":"Harrison C, Young J, Navi D, Riaz N, Lingala B, Kim Y, et al. Revisiting low-dose total skin electron beam therapy in mycosis fungoides. Int J Radiat Oncol Biol Phys. 2011;81(4). https:\/\/doi.org\/10.1016\/j.ijrobp.2011.01.023.","DOI":"10.1016\/j.ijrobp.2011.01.023"},{"issue":"2","key":"809_CR32","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jaad.2014.10.014","volume":"72","author":"RT Hoppe","year":"2015","unstructured":"Hoppe RT, Harrison C, Tavallaee M, Bashey S, Sundram U, Li S, et al. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol. 2015;72(2):286\u201392. https:\/\/doi.org\/10.1016\/j.jaad.2014.10.014.","journal-title":"J Am Acad Dermatol"},{"key":"809_CR33","doi-asserted-by":"publisher","unstructured":"Schaff EM, Rosenberg SA, Olson SJ, Howard SP, Bradley KA. Bone marrow suppression as a complication of total skin helical tomotherapy in the treatment of mycosis fungoides. Radiat Oncol. 2018;13(1). https:\/\/doi.org\/10.1186\/s13014-018-1013-2.","DOI":"10.1186\/s13014-018-1013-2"},{"key":"809_CR34","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3389\/fmed.2019.00116","volume":"6","author":"T Oka","year":"2019","unstructured":"Oka T, Miyagaki T. Novel and future therapeutic drugs for advanced mycosis fungoides and S\u00e9zary syndrome. Front Med. 2019;6:116. https:\/\/doi.org\/10.3389\/fmed.2019.00116.","journal-title":"Front Med"},{"issue":"9","key":"809_CR35","first-page":"809","volume":"84","author":"S Rupoli","year":"1999","unstructured":"Rupoli S, Barulli S, Guiducci B, Offidani M, Mozzicafreddo G, Simonacci M, et al. Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T cell lymphoma multicenter study group. Haematologica. 1999;84(9):809\u201313.","journal-title":"Haematologica"},{"issue":"3","key":"809_CR36","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1046\/j.1365-2133.1999.02704.x","volume":"140","author":"O Jumbou","year":"1999","unstructured":"Jumbou O, Guyen JM, Tessier MH, Legoux B, Dr\u00e9no B. Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa. Br J Dermatol. 1999;140(3):427\u201331. https:\/\/doi.org\/10.1046\/j.1365-2133.1999.02704.x.","journal-title":"Br J Dermatol"},{"issue":"1","key":"809_CR37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/1346-8138.12341","volume":"41","author":"M Sugaya","year":"2014","unstructured":"Sugaya M, Tokura Y, Hamada T, Tsuboi R, Moroi Y, Nakahara T, et al. Phase II study of i.v. interferon-gamma in Japanese patients with mycosis fungoides. J Dermatol. 2014;41(1):50\u20136. https:\/\/doi.org\/10.1111\/1346-8138.12341.","journal-title":"J Dermatol"},{"issue":"9","key":"809_CR38","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","volume":"19","author":"M Duvic","year":"2001","unstructured":"Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous t-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19(9):2456\u201371. https:\/\/doi.org\/10.1200\/JCO.2001.19.9.2456.","journal-title":"J Clin Oncol"},{"issue":"6","key":"809_CR39","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/j.1365-2133.2009.09037.x","volume":"160","author":"RA Abbott","year":"2009","unstructured":"Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ, et al. Bexarotene therapy for mycosis fungoides and S\u00e9zary syndrome. Br J Dermatol. 2009;160(6):1299\u2013307. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09037.x.","journal-title":"Br J Dermatol"},{"key":"809_CR40","unstructured":"Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137(5):581\u201393 Doi:10\u20131001\/pubs.Arch Dermatol.-ISSN-0003-987x-137-5-dst0039."},{"issue":"5","key":"809_CR41","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S0190-9622(03)01591-3","volume":"49","author":"HS Zackheim","year":"2003","unstructured":"Zackheim HS, Kashani-Sabet M, McMillan A. Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol. 2003;49(5):873\u20138. https:\/\/doi.org\/10.1016\/S0190-9622(03)01591-3.","journal-title":"J Am Acad Dermatol"},{"key":"809_CR42","doi-asserted-by":"publisher","first-page":"31(2)","DOI":"10.1111\/dth.12586","volume":"31","author":"S Purnak","year":"2018","unstructured":"Purnak S, Azar J, Mark LA. Etoposide as a single agent in the treatment of mycosis fungoides: a retrospective analysis. Dermatol Ther. 2018;31:31(2). https:\/\/doi.org\/10.1111\/dth.12586.","journal-title":"Dermatol Ther"},{"issue":"12","key":"809_CR43","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","volume":"125","author":"M Duvic","year":"2015","unstructured":"Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, et al. Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125(12):1883\u20139. https:\/\/doi.org\/10.1182\/blood-2014-09-600924.","journal-title":"Blood"},{"issue":"9","key":"809_CR44","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","volume":"19","author":"YH Kim","year":"2018","unstructured":"\u2022\u2022 Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192\u2013204. https:\/\/doi.org\/10.1016\/S1470-2045(18)30379-6 An open-label, international, phase III, randomized controlled trial of patients with relapsed or refractory MF\/SS showed that mogamulizumab resulted in superior progression-free survival compared with vorinostat.","journal-title":"Lancet Oncol"},{"issue":"28","key":"809_CR45","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","volume":"34","author":"S Fuji","year":"2016","unstructured":"Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34(28):3426\u201333. https:\/\/doi.org\/10.1200\/JCO.2016.67.8250.","journal-title":"J Clin Oncol"},{"issue":"32","key":"809_CR46","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","volume":"33","author":"YH Kim","year":"2015","unstructured":"Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750\u20138. https:\/\/doi.org\/10.1200\/JCO.2014.60.3969.","journal-title":"J Clin Oncol"},{"issue":"10094","key":"809_CR47","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","volume":"390","author":"HM Prince","year":"2017","unstructured":"\u2022\u2022 Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(17)31266-7 An international randomized phase III trial for MF patients with CD30 expression (at least 10% of tumor cells or lymphoid infiltrates) revealed that the proportion of patients achieving an OR lasting at least 4 months was 50% with brentuximab vedotin versus 10% with physician\u2019s choice (methotrexate or bexarotene) in MF.","journal-title":"Lancet"},{"issue":"20","key":"809_CR48","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","volume":"123","author":"SM Horwitz","year":"2014","unstructured":"Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O\u2019Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095\u2013100. https:\/\/doi.org\/10.1182\/blood-2013-12-542142.","journal-title":"Blood"},{"issue":"11","key":"809_CR49","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","volume":"101","author":"J Lundin","year":"2003","unstructured":"Lundin J, Hagberg H, Repp R, Cavallin-St\u00e5hl E, Fred\u00e9n S, Juliusson G, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/S\u00e9zary syndrome. Blood. 2003;101(11):4267\u201372. https:\/\/doi.org\/10.1182\/blood-2002-09-2802.","journal-title":"Blood"},{"issue":"7","key":"809_CR50","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1001\/jamadermatol.2013.10099","volume":"150","author":"R Watanabe","year":"2014","unstructured":"Watanabe R, Teague JE, Fisher DC, Kupper TS, Clark RA. Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: diffuse erythema as a positive predictor of complete remission. JAMA Dermatol. 2014;150(7):776\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2013.10099.","journal-title":"JAMA Dermatol"},{"issue":"21","key":"809_CR51","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","volume":"25","author":"EA Olsen","year":"2007","unstructured":"Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous t-cell lymphoma. J Clin Oncol. 2007;25(21):3109\u201315. https:\/\/doi.org\/10.1200\/JCO.2006.10.2434.","journal-title":"J Clin Oncol"},{"issue":"32","key":"809_CR52","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","volume":"27","author":"RL Piekarz","year":"2009","unstructured":"Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27(32):5410\u20137. https:\/\/doi.org\/10.1200\/JCO.2008.21.6150.","journal-title":"J Clin Oncol"},{"issue":"29","key":"809_CR53","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","volume":"28","author":"SJ Whittaker","year":"2010","unstructured":"Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(29):4485\u201391. https:\/\/doi.org\/10.1200\/JCO.2010.28.9066.","journal-title":"J Clin Oncol"},{"issue":"9","key":"809_CR54","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182\u20139. https:\/\/doi.org\/10.1200\/JCO.2010.29.9024.","journal-title":"J Clin Oncol"},{"issue":"18","key":"809_CR55","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","volume":"119","author":"SM Horwitz","year":"2012","unstructured":"Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012;119(18):4115\u201322. https:\/\/doi.org\/10.1182\/blood-2011-11-390211.","journal-title":"Blood"},{"issue":"14","key":"809_CR56","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1158\/1078-0432.CCR-16-2064","volume":"23","author":"M Duvic","year":"2017","unstructured":"Duvic M, Kim YH, Zinzani PL, Horwitz SM. Results from a phase I\/II open-label, dose-finding study of pralatrexate and oral bexarotene in patients with relapsed\/refractory cutaneous T-cell lymphoma. Clin Cancer Res. 2017;23(14):3552\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2064.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"809_CR57","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","volume":"18","author":"PL Zinzani","year":"2000","unstructured":"Zinzani PL, Baliva G, Magagnoli M, Bendandi M, Modugno G, Gherlinzoni F, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol. 2000;18(13):2603\u20136. https:\/\/doi.org\/10.1200\/JCO.2000.18.13.2603.","journal-title":"J Clin Oncol"},{"issue":"1","key":"809_CR58","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","volume":"7","author":"M Duvic","year":"2006","unstructured":"Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2006;7(1):51\u20138. https:\/\/doi.org\/10.3816\/CLM.2006.n.039.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"11","key":"809_CR59","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1002\/cncr.21449","volume":"104","author":"E Marchi","year":"2005","unstructured":"Marchi E, Alinari L, Tani M, Stefoni V, Pimpinelli N, Berti E, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer. 2005;104(11):2437\u201341. https:\/\/doi.org\/10.1002\/cncr.21449.","journal-title":"Cancer"},{"issue":"6","key":"809_CR60","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/archderm.144.6.727","volume":"144","author":"G Quereux","year":"2008","unstructured":"Quereux G, Marques S, Nguyen JM, Bedane C, D\u2019incan M, Dereure O, et al. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or S\u00e9zary syndrome. Arch Dermatol. 2008;144(6):727\u201333. https:\/\/doi.org\/10.1001\/archderm.144.6.727.","journal-title":"Arch Dermatol"},{"issue":"1","key":"809_CR61","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2133.2005.06682.x","volume":"153","author":"G Di Lorenzo","year":"2005","unstructured":"Di Lorenzo G, Di Trolio R, Delfino M, De Placido S. Pegylated liposomal doxorubicin in stage IVB mycosis fungoides. Br J Dermatol. 2005;153(1):183\u20135. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06682.x.","journal-title":"Br J Dermatol"},{"issue":"3","key":"809_CR62","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1046\/j.1365-2141.2001.02919.x","volume":"114","author":"E Olavarria","year":"2001","unstructured":"Olavarria E, Child F, Woolford A, Whittaker SJ, Davis JG, McDonald C, et al. T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol. 2001;114(3):624\u201331. https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02919.x.","journal-title":"Br J Haematol"},{"issue":"8","key":"809_CR63","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.bbmt.2009.04.017","volume":"15","author":"PA Wu","year":"2009","unstructured":"Wu PA, Kim YH, Lavori PW, Hoppe RT, Stockerl-Goldstein KE. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and S\u00e9zary syndrome. Biol Blood Marrow Transplant. 2009;15(8):982\u201390. https:\/\/doi.org\/10.1016\/j.bbmt.2009.04.017.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"29","key":"809_CR64","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","volume":"28","author":"RF Duarte","year":"2010","unstructured":"Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a retrospective analysis of the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2010;28(29):4492\u20139. https:\/\/doi.org\/10.1200\/JCO.2010.29.3241.","journal-title":"J Clin Oncol"},{"issue":"29","key":"809_CR65","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1200\/JCO.2014.57.5597","volume":"32","author":"RF Duarte","year":"2014","unstructured":"Duarte RF, Boumendil A, Onida F, Gabriel I, Arranz R, Arcese W, et al. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and s\u00e9zary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol. 2014;32(29):3347\u20138. https:\/\/doi.org\/10.1200\/JCO.2014.57.5597.","journal-title":"J Clin Oncol"},{"issue":"11","key":"809_CR66","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/bmt.2014.161","volume":"49","author":"MJ Lechowicz","year":"2014","unstructured":"Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, Wiernik PH, et al. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant. 2014;49(11):1360\u20135. https:\/\/doi.org\/10.1038\/bmt.2014.161.","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"809_CR67","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1093\/annonc\/mdv473","volume":"26","author":"C Hosing","year":"2015","unstructured":"Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015;26(12):2490\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdv473.","journal-title":"Ann Oncol"},{"key":"809_CR68","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/hon.2719","volume":"38","author":"T Mori","year":"2020","unstructured":"Mori T, Shiratori S, Suzumiya J, Kurokawa M, Shindo M, Naoyuki U, et al. Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and S\u00e9zary syndrome. Hematol Oncol. 2020;38:266\u201371. https:\/\/doi.org\/10.1002\/hon.2719.","journal-title":"Hematol Oncol"},{"issue":"1","key":"809_CR69","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1346-8138.2012.01639.x","volume":"40","author":"M Sugaya","year":"2013","unstructured":"Sugaya M, Hamada T, Kawai K, Yonekura K, Ohtsuka M, Shimauchi T, et al. Guidelines for the management of cutaneous lymphomas (2011): a consensus statement by the Japanese Skin Cancer Society - lymphoma study group. J Dermatol. 2013;40(1):2\u201314. https:\/\/doi.org\/10.1111\/j.1346-8138.2012.01639.x.","journal-title":"J Dermatol"},{"issue":"8","key":"809_CR70","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","volume":"42","author":"F Trautinger","year":"2006","unstructured":"Trautinger F, Knobler R, Willemze R, Peris K, Stadler R, Laroche L, et al. EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome. Eur J Cancer. 2006;42(8):1014\u201330. https:\/\/doi.org\/10.1016\/j.ejca.2006.01.025.","journal-title":"Eur J Cancer"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00809-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-020-00809-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00809-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T22:42:37Z","timestamp":1613688157000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-020-00809-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["809"],"URL":"https:\/\/doi.org\/10.1007\/s11864-020-00809-w","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"20 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Hiroaki Kamijo declares that he has no conflict of interest.Tomomitsu Miyagaki declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"10"}}